The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes
| Autor: | Stephanie A. Amiel, Sherwyn Schwartz, Simon Heller, David G. Maggs, Ian A. Macdonald, Orville G. Kolterman, Christian Weyer, L J Klaff, James A. Ruggles |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Amyloid Epinephrine Hydrocortisone Endocrinology Diabetes and Metabolism medicine.medical_treatment Amylin Type 2 diabetes Norepinephrine Endocrinology Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Insulin Type 1 diabetes Dose-Response Relationship Drug business.industry Human Growth Hormone Middle Aged medicine.disease Glucagon Pramlintide Hypoglycemia Islet Amyloid Polypeptide Clinical trial Postprandial Diabetes Mellitus Type 1 Drug Therapy Combination Female business Hormone medicine.drug |
| Zdroj: | Diabetes, obesitymetabolism. 7(5) |
| ISSN: | 1462-8902 |
| Popis: | Background: Pramlintide, a human amylin analogue, is a potential new adjunctive therapy to insulin for patients with type 1 diabetes and insulin-using patients with type 2 diabetes. Early clinical trials have shown a transient increased risk of hypoglycaemia in some patients at the time of initiating pramlintide therapy. This may be the result of combining the postprandial glucose, lowering effect of pramlintide with the existing hypoglycaemic potential of insulin without appropriate adjustment of insulin doses. However, the possibility that pramlintide may exert an independent detrimental effect on the physiological responses to insulin-induced hypoglycaemia needs to be excluded. Methods: We conducted three separate randomized, placebo-controlled studies in patients with type 1 diabetes treated with adjunctive pramlintide. These studies utilized pramlintide at high doses (either 0.1–1 mg pramlintide daily or 0.1–0.8 mg pramlintide four times a day for 5 or 6 days) as well as doses closer to those anticipated for therapeutic usage (30, 100 or 300 µg three times daily for 14 days), and examined the hormonal, metabolic and symptomatic responses to an insulin-infusion hypoglycaemic challenge conducted at baseline and after days of therapy. Results and conclusion: Pramlintide had no effect on the counter-regulatory hormonal, metabolic and symptomatic responses to hypoglycaemia. These findings demonstrated that pramlintide, when used as adjunctive therapy to insulin in patients with type 1 diabetes, has no independent effect on the response to hypoglycaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text